![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 46, 32750-32756, November 12, 1999
From the Department of Oncological Sciences, Huntsman Cancer
Institute, University of Utah, Salt Lake City, Utah 84112-5330
Members of the Mad family of bHLHZip proteins
heterodimerize with Max and function to repress the transcriptional and
transforming activities of the Myc proto-oncogene. Mad:Max heterodimers
repress transcription by recruiting a large multi-protein complex
containing the histone deacetylases, HDAC1 and HDAC2, to DNA. The
interaction between Mad proteins and HDAC1/2 is mediated by the
corepressor mSin3A and requires sequences at the amino terminus of the
Mad proteins, termed the SID, for Sin3
interaction domain, and the second of four
paired amphipathic Transcriptional regulation depends on the assembly of large
multiprotein complexes. For example, the preinitiation complex (1),
chromatin remodeling complexes (2, 3), and histone deacetylase-containing corepressor complexes (4, 5) have been shown to
be in the 1-2 × 106 dalton size range. Molecular
connections between proteins in these molecular machines, and the
structural basis of their assembly, are not well understood. Initially,
transcription repression domains were defined by structure/function
analysis, which revealed that, like activation domains, they are more
likely to contain particular amino acids rather than have easily
identifiable protein-protein interaction domains. This finding led to
the hypothesis that activation and repression domains share similar
molecular targets and that the structure of the activation or
repression domain in itself was not required for function.
Transcriptional repressors function by at least three distinct
mechanisms: by direct contact with components of the basal
transcriptional machinery, e.g. even-skipped (6), Dr1 (7),
and MOT1 (8); by tethering histone deacetylase-containing
corepressor complexes to the promoter, e.g. the Mad family
(9, 10), Rb (11-13), and MeCP2 (14, 15); or by tethering corepressors
that lack deacetylase activity to the promoter, e.g. hairy
(16) and MAT Reversible acetylation of the amino-terminal tails of core histones
plays an important role in the regulation of gene expression. In
general, regions of chromatin that are hyperacetylated are transcriptionally active, while hypoacetylated regions are silenced (21). The recent discovery that several transcriptional co-activators are histone acetyltransferases and that co-repressor complexes contain
histone deacetylases as active components has provided a mechanistic
basis for this correlation (22-26). mSin3A and mSin3B were identified
as corepressors required for the transcriptional and biological
activities of the Mad proteins (27, 28). mSin3A has recently been shown
to be a component of a large multi-protein complex(s) that also
contains the histone deacetylases
HDAC11 and HDAC2 in
apparently stoichiometric amounts. The enzymatic activities of the
mSin3A-bound HDACs are required for full transcriptional repression by
the Mad family proteins (9, 10, 29). Subsequently, the mSin3A·HDAC
complex has been implicated as a corepressor utilized by a diverse and
rapidly expanding collection of transcriptional repressors, including
RXR, MeCP2, estrogen receptor, RPX, and Pit1 (14, 15, 30-32).
mSin3A and mSin3B and their Saccharomyces cerevisiae
orthologue SIN3 each contain four similar domains each suggested to
form two amphipathic The Mad family of basic region-helix-loop-helix-leucine zipper
(bHLHZip) proteins functions as transcriptional repressors and
antagonize the transcriptional and transforming activity of the Myc
proto-oncogenes (35-39). Currently, four Mad family members have been
identified: Mad1, Mxi1, Mad3, and Mad4 (35, 38, 40). These proteins
share extensive sequence homology throughout their entire open reading
frames, with the highest degree of conservation within the bHLHZip and
for mSin3 interaction domains (SID)
(38). The bHLHZip domain is required for dimerization with the bHLHZip protein Max and DNA binding, while the SID is required for interaction with mSin3A or mSin3B (28, 35, 38). This SID sequence from Mad1 has
been modeled as an amphipathic Several lines of experimental evidence suggest that interaction between
the Mad proteins and Mnt and mSin3A or mSin3B is critical for their
function as transcriptional repressors. Mad1 proteins with point
mutations in the SID no longer repress transcription, block Myc+Ras
cotransformation, or arrest cells in the G1 phase of the
cell cycle (27, 36, 42). Similarly, deletions of amino-terminal regions
that contain the SID in Mad3, Mad4, and Mnt severely affect their
biological function (38, 41). Finally, Mxi1 is encoded by two
alternatively spliced mRNAs, only one of which encodes a Mxi1
protein with a SID. This protein, Mxi1-SR is much more potent at
blocking Myc+Ras cotransformation than is an Mxi1 isoform which lacks a
SID (28). In order to better understand the interaction between Mad
family members and their corepressor mSin3A we have delineated the
minimal functional SID, determined key contact residues required for
interaction with PAH2 and demonstrated that the minimal SID domain is
helical in solution.
Cloning and Interaction Assays--
Fusions to the LexA DNA
binding domain were made either by polymerase chain reaction amplifying
SID 1-57 and SID 1-27 using pSPMad1 or pSPMad1(L12P/A16P) (27) as
template or by inserting a double-stranded oligonucleotide cassette
encoding the various SID constructs between the EcoRI and
BamHI sites of pBTM116 (43). Each construct was verified by
sequencing. The different LexA fusion constructs and VP16PAH2 (27) were
introduced into the S. cerevisiae strain L40 by lithium
acetate transformation (44). Quantitative Transcription Assays--
293 cells were grown in Dulbecco's
modified Eagle's medium with 10% defined calf serum (HyClone). 2 × 105 cells were plated on 60-mm dishes and transfected
with 200 ng of the GAL4-14D luciferase reporter (45) and 1 µg of the
indicated expression vector. Cells were harvested 24 h after
transfection and luciferase and Peptide Synthesis--
The four SID-containing peptides were
synthesized and purified by the Huntsman Cancer Institute DNA/Peptide
Resource Core Facility. Each peptide includes residues 7-20 of human
Mad1. The sequence of the wild type SID peptide is GGGMNIQMLLEAADYLE.
The sequence of the double mutant L12P/A16P SID is GGGMNIQMPLEAPDYLE. The sequences of the two single mutant peptides A15D SID and L19D SID
are GGGMNIQMLLEDADYLE and GGGMNIQMLLEAADYDE, respectively. Peptide
concentrations were determined by measuring the absorbance of the
peptide at 280 nm and using the extinction coefficient for a single
tyrosine of 1.49 × 103 M Circular Dichroism (CD) Spectroscopy--
CD samples contained
50 µM of peptide, 1× phosphate-buffered saline, and the
percentage of trifluoroethanol (TFE, Sigma) indicated in Fig. 4. CD
spectra were collected on an Aviv 62DS spectrophotometer from 280 to
195 nm at 25 °C using a cell with a 0.1-cm pathlength. The reported
spectra are the average of 15 consecutive runs. The observed
ellipticity was converted to mean residue molar ellipticity [ Far Western Blotting--
Mad1His and Mad1(L12P/A16P)His (27),
which have a polyhistidine tag fused to their carboxyl termini, were
translated in vitro in 50-µl reactions using the TNT
coupled reticulocyte lysate system (Promega) and
35[S]methionine (NEN Life Science Products) and were
purified under native or denaturing conditions. Ni2+-NTA
agarose (Qiagen) was blocked with rabbit reticulocyte lysate (diluted
1:3 in PBS) for 30 min at 4 °C and then incubated with the in
vitro synthesized Mad1His and Mad1(L12P/A16P)His for 30 min at
4 °C in PBS (native) or 6 M guanidine hydrochloride, 0.1 M NaH2PO4, and 0.01 M
Tris, pH 8.0 (denaturing conditions) followed by extensive washing with
the same buffers. The bound proteins were eluted in PBS containing 0.5 M imidazole and then dialyzed overnight against PBS to
remove the imidazole and allow for renaturation. Recombinant GST and
GST-PAH2 were expressed in bacteria and purified on
glutathione-Sepharose 4B (Amersham Pharmacia Biotech). The blots were
prepared by resolving 1 µg of GST and 1 µg of GST-PAH2 on 15%
SDS-PAGE, followed by transfer to PVDF membrane. The blots were blocked
in far Western buffer (PBS containing 0.1% Nonidet P-40, 1 mM EDTA, and 1 mM dithiothreitol) containing
5% nonfat dry milk for 1 h at 4 °C. Purified probes were added
to blots in 5 ml of far Western buffer containing 1% nonfat dry milk
and incubated together at 4 °C overnight with rocking. Following
washing with far Western buffer, the blots were air-dried and exposed 48 h for autoradiography.
Mad1 and mSin3A Interact Directly--
We wished to determine the
structural requirements for the interaction between mSin3A and Mad1.
However, it has not been conclusively demonstrated that the interaction
between the two proteins is direct. For example, the interaction
between Mad1 and mSin3A has been detected using the two-hybrid assay,
in vitro translated proteins, and co-immunoprecipitation
from cell extracts containing epitope-tagged Mad1 (10, 27, 28). While
these experiments suggest that the interaction between Mad1 and mSin3A
is direct, they do not rule out the possibility that a bridging factor
could mediate the interaction between Mad1 and mSin3A.
To determine whether the interaction between Mad1 and mSin3A is direct,
we used far Western blot assays. In these experiments GST-PAH2, a GST
fusion to the PAH2 domain of mSin3A, and GST alone were resolved by
SDS-PAGE followed by transfer to a PVDF membrane. Duplicate blots were
probed with 35S-labeled in vitro transcribed and
translated Mad1His and mutant Mad1 protein, Mad1(L12P/A16P)His, that
does not interact with mSin3A. Equal efficiency of transcription and
translation of these proteins was confirmed by SDS-PAGE followed by
autoradiography to detect the proteins (data not shown). These protein
probes were purified on Ni2+-NTA agarose under native or
denaturing conditions. When purified under native conditions, Mad1His
but not Mad1(L12P/A16P)His was able to interact with GST-PAH2. Neither
Mad1His nor Mad1(L12P/A16P)His interacted with GST alone (Fig.
1A). Together, these results
confirm that Mad1 interacts specifically with PAH2 of mSin3A and that the interaction is sensitive to mutations in the SID. However, because
there is abundant mSin3A, and presumably interacting cofactors, in
reticulocyte lysate (data not shown), the possibility exists that a
bridging factor may have copurified with Mad1 under native conditions
and that it mediated the interaction between Mad1 and PAH2. Mad1His
purified under denaturing conditions and subsequently renatured also
interacted with GST-PAH2 but not with GST alone (Fig. 1B,
left panel). Furthermore, Mad1(L12P/A16P)His
purified under denaturing conditions did not interact with either GST
or GST-PAH2 (Fig. 1B, right panel). It
is very likely that any interaction between Mad1 and a putative
bridging factor would have been disrupted under the denaturing
conditions used for purification. Therefore, these results indicate
that the interaction between Mad1 and PAH2 of mSin3A is direct and does
not require a bridging factor.
The SID Is an Amphipathic
We have used a directed two-hybrid assay to measure the relative
affinity of the SID and various SID mutants for PAH2. Briefly, SID
molecules based on the sequence of human Mad1 were fused to the DNA
binding domain of bacterial LexA, and the PAH2 domain of mSin3A was
fused to the transcriptional activation domain of VP16. Following
introduction into the S. cerevisiae strain L40, relative
affinity was measured by quantitative analysis of the
To define the minimal sequence required for interaction with PAH2, we
constructed a series of amino- and carboxyl-terminal truncations of the
SID. Consistent with previous findings (27), the region from the
initiating methionine to the beginning of the basic region, amino acids
1-57, was sufficient for interaction and two point mutations within
the putative
To determine which residues of the minimal SID are required for
interaction with PAH2, we first displayed residues 7-20 on a helical
wheel (Fig. 3A). This
conceptual
Mutation of any of the presumptive contact hydrophobic residues,
Ala-15, Tyr-18, or Leu-19, to aspartic acid severely impaired binding.
Our original double mutant, L12P/A16P (27), failed to interact with
PAH2, suggesting that these residues may be involved in direct contact
between the SID and PAH2. Alternatively, it is possible that the double
proline mutations disrupt the helical nature of the SID and the mutant
fails to interact for this reason. To further test whether these
residues are involved directly in the interaction, amino acids 12 and
16 were mutated in tandem to glutamic and aspartic acid, respectively.
We predicted that these alterations would not disrupt the helical
nature of the SID, but would no longer make hydrophobic interactions.
Like the single mutants at the presumptive contact interface, this
double mutant was incapable of high affinity interaction with PAH2.
This mutational analysis is consistent with the hypothesis that the SID
forms an amphipathic
To test directly if the SID could adopt an
Recently, it was demonstrated that TFE destabilizes the unfolded state
of a peptide that indirectly enhances the folding of the helix (49).
Therefore, we were concerned that any peptide, regardless of its
inherent helical content, might be forced into a helical structure at
high TFE concentrations. Unlike the wild type SID, however, the spectra
of a SID peptide with two putative
The SID mutant L12E/A16D is unable to interact with PAH2 (Fig.
3B). We hypothesized that, unlike the helix-destabilizing
proline substitutions, this mutant peptide's loss of binding may have resulted from disruption of hydrophobic interactions required for
contact with PAH2 rather than disruption of helical structure. However,
the CD spectrum of L12E/A16D SID indicates that in 50% TFE this
peptide is not as helical as the wild type peptide and shows only
slightly more helical nature than L12P/A16P SID (data not shown). Thus,
these mutations appear to affect the structure of the SID, making it
impossible to discern whether the inability of this mutant to interact
with PAH2 in the two-hybrid is due to disruption of hydrophobic
interactions or the disruption of secondary structure. In an attempt to
clarify the role of the hydrophobic residues of the SID, we collected
the CD spectra for the two single mutant peptides, A15D SID and L19D
SID. The spectrum for L19D SID was nearly identical to that collected
for the wild type SID, while the spectrum for A15D showed that it was
slightly less helical than the wild type SID, indicating that both
mutant peptides are primarily helical in 50% TFE (Fig.
5, A-C). Calculation of
percentage helicity for the peptides indicated that the mutations A15D
and L19D reduced the helicity, of the SID relative to wild type, by
approximately 40% and 5%, respectively. Therefore, A15D SID and L19D
SID retain helical structure but are unable to interact with PAH2 in
the two-hybrid. This suggests that the hydrophobic face of the SID
Amino Acids 8-20 of Mad1 Functions as a Portable Repression
Domain--
Our mutational analysis suggests that a 13-amino acid
amphipathic To understand the structural basis for the direct interaction
between the transcriptional repressor Mad1 and its corepressors mSin3A
and mSin3B, we defined the minimal sequence of Mad1 required for
interaction with PAH2, showed that this minimal interaction domain can
adopt an amphipathic We have used two classes of mutations to determine the structural
requirements for the interaction between the SID and PAH2. The first
class (L12P/A16P SID and L12E/A16D SID) cannot adopt an We believe that the helical nature of the 14-amino acid SID peptide
observed in our CD experiments is likely to reflect its structure in
the context of full-length Mad1. The double proline mutant SID peptide
is incapable of The dependence of the interaction between the repression domain of Mad1
and mSin3A on an amphipathic helical structure is reminiscent of the
interaction between several activation domains and their target
proteins. The p53 activation domain and the KID domain of CREB bury the
hydrophobic faces of their helical activation domains into hydrophobic
pockets in MDM2 and the KIX domain of CBP, respectively (18, 19). Also,
the acidic activation domain of VP16 forms an amphipathic Another important feature emerging from structural studies on
activation domains is that they tend to be unstructured in the absence
of their target and adopt their helical structure upon binding (19, 20,
53). Each of our mutant SIDs containing alanine substitutions at
non-contact residues interact with PAH2 approximately 2-fold better
that the wild type. Because substitutions to alanine at these positions
may promote helicity, we speculate that the SID may be unstructured in
the absence of PAH2 and that alanine substitution at noncontact
residues lowers the activation energy required for the SID to undergo
the transition from random coil to helix.
It is not clear what structural features of PAH2 will be required for
interaction with the SID. The PAH domains were originally suggested to
consist of two amphipathic helices, helix A and B, separated by a
flexible linker (33). Proline insertions into helix A of PAH2 and
deletion of either the helix A or B of PAH2 eliminate binding to Mad1
or Mxi1, demonstrating the importance of these putative structures for
interaction (28, 45). It may be that the PAH2 domain is most
structurally similar to the KIX domain of CBP. The KIX domain consists
of three The minimal SID contains 13 amino acids and is rich in hydrophobic
amino acids. One mutant SID, Q10A/E14A/D17A, has hydrophobic amino
acids at 10 of its 13 positions and binds 2-fold better than wild type.
Therefore, the SID may be characterized as a hydrophobic region of
amino acids. However, given that regions of hydrophobic amino acids are
relatively common in proteins, it seems unlikely that other mSin3A/B
interacting proteins will be identified through simple searches of
protein data bases. Several other proteins have been identified that
interact with the PAH domains of mSin3A and/or B. The 91 carboxyl-terminal residues of SAP30 interact with PAH3 (30). Two
regions of N-CoR interact with mSin3A: residues 1-312 interact with
PAH3, and residues 1829-1940 interact with PAH1 (31, 34). SAP30 and
the amino-terminal portion of N-CoR lack regions with obvious sequence
similarity to the Mad1 SID; however, deletion of an alanine-rich
putative The 15-amino acid region following the SID, residues 20-35, is highly
conserved but it is only found in the vertebrate Mad family proteins.
This conserved region is apparently not required for interaction with
PAH2, and may have a destabilizing effect on the SID PAH2 interaction.
Further, the minimal 13-amino acid SID functions similarly to the
longer 35-amino acid SID in transcription repression experiments,
suggesting that residues 20-35 are relatively unimportant for
transcription repression. It is possible that this conserved domain
plays an ancillary role in binding to PAH2 and repression, but this
function is not revealed by the assays employed here. Because the Mad
family and Mnt have overlapping, if not identical, DNA binding
specificities (35, 38, 40, 41), it is possible that the residues 20-35
may themselves function as a protein-protein interaction domain that
will distinguish activity of the Mad family from Mnt or other
transcription repressor families that depend on SID-like domains for function.
We thank Owen Pornillos and Wes Sundquist for
help with CD spectroscopy, and Wes Sundquist and Jennifer Logan for
critical reviews of the manuscript.
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by National Institutes of Health Grant GM5568-01. Scholar
of the Leukemia Society of America. To whom correspondence should be
addressed: Dept. of Oncological Sciences, Huntsman Cancer Inst.,
University of Utah, 2000 Circle of Hope, Salt Lake City, UT 84112-5330. Tel.: 801-581-5597; Fax: 801-585-1980; E-mail: don.
ayer@hci.utah.edu.
2
A. N. Billin and D. E. Ayer,
unpublished results.
The abbreviations used are:
HDAC1, histone
deacetylase 1;
HDAC2, histone deacetylase 2;
bHLHZip, basic
region-helix-loop-helix-zipper;
SID, mSin3 interaction domain;
PAH, paired amphipathic helix;
CD, circular dichroism;
TFE, trifluoroethanol;
PBS, phosphate-buffered saline;
GST, glutathione
S-transferase;
PVDF, polyvinylidene fluoride;
GALDBD, GAL4
DNA binding domain;
KID, kinase-inducible domain;
deg, degree(s);
PAGE, polyacrylamide gel electrophoresis.
A 13-Amino Acid Amphipathic
-Helix Is Required for the
Functional Interaction between the Transcriptional Repressor Mad1
and mSin3A*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helices
(PAH2) in mSin3A. To better understand the requirements for the
interaction between the SID and PAH2, we have performed mutagenesis and
structural studies on the SID. These studies show that amino acids
8-20 of Mad1 are sufficient for SID:PAH2 interaction. Further, this
minimal 13-residue SID peptide forms an amphipathic
-helix in
solution, and residues on the hydrophobic face of the SID helix are
required for interaction with PAH2. Finally, the minimal SID can
function as an autonomous and portable repression domain, demonstrating that it is sufficient to target a functional mSin3A/HDAC corepressor complex.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
2-MCM1 (17). In each of these cases, little or no
structural data are available for the repression domain. In contrast,
one theme that has emerged recently from the study of activation
domains is that relatively short stretches of amino acids can adopt
amphipathic
-helical structures and mediate stable functional
interactions between transcriptional activators and coactivators
(18-20).
-helices separated by a flexible linker (27, 33). These regions, termed PAH domains for paired
amphipathic
-helix, were originally proposed
to function as protein-protein interaction domains (33). Recent
experiments have demonstrated this to be the case. For example, Mad
proteins interact with PAH2 (27, 28), a repression domain of the
nuclear hormone corepressor N-CoR interacts with PAH1 (31, 34) and the
mSin3 interacting protein SAP30 binds to PAH3 (30). The four PAH
domains of the different Sin3 proteins are highly conserved. For
example, PAH2 is 90% similar between mSin3A and mSin3B and it is
approximately 70% similar to the PAH2 domain of S. cerevisiae SIN3 (27) and recently identified SIN3 homologues from
Schizosaccharomyces pombe, Caenorhabditis
elegans, Drosophila melanogaster, and Arabidopsis thaliana (data not shown). Within a given protein, the four PAH domains are roughly 45% similar with the hydrophobic positions of the
putative amphipathic
-helices being most highly conserved, suggesting that PAH domains may share structural features (27). With
the exception of the Mad family, the domains required for SIN3 binding
of the other SIN3 interacting proteins, SAP30, SAP18, N-CoR, UME6,
HDAC1, and HDAC2, etc., share no obvious sequence similarity (data not shown).
-helix (27). Recently, another
bHLHZip protein termed Mnt, which shares homology to the Mad family
within these two regions, has been identified. Mnt also interacts with
Max and can repress transcription in a mSin3-dependent manner and therefore appears to be functionally equivalent to the Mad
family proteins (41).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-galactosidase assays were
performed from three independent colonies in triplicate from liquid
cultures (44). For each measurement the standard deviation was less
than 10%.
-galactosidase activity measured
according to the manufacturers' protocols (Promega and Tropix). Each
transfection was performed at least twice in triplicate. Error shown is
the standard of the mean.
1
cm
1.
]
(deg cm2 dmol
1) using the relationship
[
]=
/(Cr l) where
is the
observed ellipticity, l is the pathlength, and
Cr is the mean residue molar concentration.
Fractional helicities were calculated as described using values for
[
]0222 and
[
]100222, corresponding to 0% and 100%
helical content at 222 nm, of
2000 and
28,400 deg cm2
dmol
1, respectively (46).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (42K):
[in a new window]
Fig. 1.
The interaction between the SID and PAH2 is
direct. PVDF blots with immobilized GST and GST-PAH2 were probed
with 35S-labeled IVT Mad1His (left panel) and
Mad1(L12P/A16P)His (right panel) that had been purified
either under native (A) or denaturing (B)
conditions. The blots were dried and then exposed to detect bound
35S-labeled proteins. Equivalent amounts of GST and
GST-PAH2 were immobilized in each membrane.
-Helix--
Alignment of the Mad
family proteins and Mnt from different species reveals that amino acids
7-35, numbering relative to Mad1, are highly conserved (Fig.
2A). Within this block of
residues, the sequence LLEAA is nearly identical between the aligned
molecules, suggesting that it may form the core of the interaction
domain. This block of conservation is followed by a stretch of charged amino acids and the sequence EHGYAS. These downstream sequence elements
are highly conserved within the mammalian Mad proteins but are absent
from the Mnt proteins and an invertebrate Mad homologue. Previous
mutagenesis studies in which the first 35 amino acids of Mad1 were
deleted have demonstrated that this conserved amino-terminal region is
necessary for interaction between Mad proteins and mSin3A (27). Another
Mad1 truncation in which the first 20 amino acids of Mad1 are deleted
but leaves the EHGYAS region intact was also tested. This deletion was
also unable to interact with mSin3A, indicating that the conserved
EHGYAS region is not sufficient for the Mad1:mSin3A interaction (27).
Further experiments have shown that amino acids 1-35 of Mad1 mediate
histone deacetylase-dependent repression (9, 10, 27, 38,
41). However, the minimal domain required for the interaction between
Mad1 and mSin3A and the role, if any, of the conserved EHGYAS region in
this interaction have not been determined.

View larger version (55K):
[in a new window]
Fig. 2.
Determination of the minimal SID. The
amino termini of the Mad family members and Mnt were aligned using the
GCG pileup algorithm (A). Regions of highest conservation
are boxed. Amino acid positions 10, 14, and 17, numbering relative to
Mad1, of the SID which are somewhat divergent among these proteins are
marked with a filled circle. Interactions between the SID and the PAH2
domain were measured by a directed two-hybrid assay (B).
Amino acids 251-404 of mSin3A encoding the PAH2 domain were fused to
the VP16 activation domain and the SID and various mutants were fused
to the LexA DNA binding domain. The sequences of the different SID
amino- or carboxyl-terminal deletion mutants are shown along with the
relative
-galactosidase activity of each SID in combination with
VP16PAH2 in the yeast strain L40. For SID 1-57, only amino acids 1-27
are shown. The
-galactosidase activity of each mutant was normalized
to that measured for LexA fused to amino acids 1-57 of Mad1 in
combination with VP16PAH2.
-galactosidase
activity generated from an integrated LexA-dependent LacZ
reporter gene.
-helical region of the SID, L12P/A16P, completely
abolished interaction (Fig. 2B). A carboxyl-terminal
deletion of 30 amino acids, SID 1-27, which removes the conserved
EHGYAS, bound PAH2 almost 2-fold better than the longer amino-terminal
construct, suggesting that the EHGYAS sequence has a slight negative
effect on binding (Fig. 2B). Again, in the context of this
protein, the L12P/A16P double mutation completely abolished
interaction. Further deletion analysis demonstrated that amino acids
8-20 are necessary and sufficient for interaction. These findings
suggest that the highly conserved region between amino acids 20-35
found in the vertebrate Mad proteins is completely dispensable for
interaction and that the sequences that are conserved between Mad
proteins across species and Mnt constitute a minimal SID.
-helix is amphipathic. The three residues that are less
conserved within the Mad family and Mnt, positions Gln-10, Glu-14 and
Asp-17, all lie on the hydrophilic face of the
-helix. Given the
charged nature of the hydrophilic face and the lower conservation of
Gln-10, Glu-14, and Asp-17, this surface is predicted not to be
involved in the SID:PAH2 interaction. In contrast, the highly conserved
hydrophobic face of this putative
-helix is predicted to mediate
protein-protein interaction. To determine which face of the SID is
required for interaction with PAH2, we mutated several amino acids in
the context of the minimal 13-amino acid SID (Fig. 3B). As
predicted, mutation of the presumptive noncontact face had little
effect on interaction. A SID peptide containing a Q10R mutation reduced
binding 4-fold, while three single mutations to alanine, Q10A, E14A,
and D17A, could bind to PAH2 with approximately 2-fold higher affinity.
A protein containing all three alanine mutations (Q10A/E14A/D17A) bound
PAH2 with affinity similar to each of the single alanine mutants,
further supporting the hypothesis that these residues are not involved
in the interaction. In addition, because alanine substitutions are
thought to be compatible with helical structure, this finding is
consistent with the predicted helicity of the SID.

View larger version (35K):
[in a new window]
Fig. 3.
Determination of residues required for
interaction between the SID and PAH2. Amino acids 7-20 of Mad 1 are modeled as an amphipathic
-helix (A). Hydrophobic and
charged residues are circled and boxed, respectively. Amino acids 10, 14, and 17 are potential non-contact residues and are enclosed in a
shaded box. The amino acid residues that were mutated are
also indicated. The sequences of the different SID point mutants are
shown along with the relative
-galactosidase activity of each SID in
combination with VP16PAH2 in the yeast strain L40 (B). The
-galactosidase activity of each mutant was normalized to that
measured for LexA fused to amino acids 8-20 of wild type Mad1 in
combination with VP16PAH2.
-helix with the hydrophobic face serving as the
contact interface with PAH2.
-helical structure, we
measured the helical content of wild type SID and mutant SID peptides
using circular dichroism (CD) spectroscopy. Short peptides do not
generally form secondary structures in aqueous solutions because the
solvent competes for structure-stabilizing intramolecular hydrogen
bonds. Therefore, spectra for the wild type and mutant SID peptides
were measured in the solvent TFE, which is commonly used to stabilize
-helical conformation in peptides that have an inherent helical
propensity (47, 48). In an aqueous solution containing 1% TFE, the
wild type SID peptide lacks secondary structure (Fig.
4A). At increasing TFE
concentrations, the wild type peptide adopts an
-helical structure
as indicated by the strong negative peaks at 208 and 222 nm. In 20%
TFE the SID is approximately 40%
-helical. This percentage
increases to approximately 60% in 50% TFE. Thus, as predicted the
wild type SID has helical propensity and is able to adopt an
-helical conformation.

View larger version (20K):
[in a new window]
Fig. 4.
The wild type SID peptide has an inherent
helical propensity. The CD spectra of wild type SID and L12P/A16P
SID peptides were measured in 1, 20, and 50% TFE. The CD spectra of
the wild type SID peptide (A) and the L12P/A16P SID peptide
(B) are shown. Percentages of TFE are denoted as follows:
open squares, 1% TFE; shaded triangles, 20%
TFE; filled circles, 50% TFE.
-helix-destabilizing proline
substitutions, L12P/A16P, remained relatively unchanged with increasing
concentrations of TFE, demonstrating that it does not undergo a
transition from random coil to
-helix (Fig. 4B). We infer
that the
-helical structure observed with the wild type SID peptide
in TFE is a reflection of its helical propensity. These results, along
with those from the directed two-hybrid assay, suggest that the SID
must adopt an
-helical conformation to allow interaction with PAH2.
-helix, which is disrupted in these mutants, is important for
interaction with PAH2.

View larger version (11K):
[in a new window]
Fig. 5.
Mutant SIDs that are unable to interact with
PAH2 have an inherent helical propensity. The CD spectra of wild
type SID peptide (A), A15D SID peptide (B), and
L19D SID peptide (C) measured in 50% TFE are shown.
-helix mediates the interaction between the SID and
PAH2. To test whether this minimal 13-residue interaction domain is sufficient to target a functional mSin3·HDAC corepressor complex to
DNA, we fused amino acids 8-20 from Mad1 to the DNA binding domain of
the yeast transcriptional activator GAL4 (GALDBD). The transcriptional
activity of GALSID(8-20) WT was tested on a reporter containing four
GAL4 binding sites cloned upstream of a minimal promoter (Fig.
6A). Consistent with our
previous findings (45), the GALDBD alone activates this reporter
approximately 3-fold, and a fusion between the first 35 amino acids of
Mad1 and the GALDBD repressed this level of reporter activity
approximately 7-fold. GALSID(8-20) WT repressed transcription to
approximately the same level when fused to the GAL4 DNA binding domain
(Fig. 6B), suggesting that this minimal SID is sufficient to
target functional mSin3·HDAC complexes to DNA. Amino acids 10, 14, and 17 of the SID can be mutated to alanine without adversely affecting the interaction with PAH2 (Fig. 3). However, it is possible that these
residues constitute a surface that interacts with other components of
the mSin3·HDAC complex and/or components of the general
transcriptional machinery. To test whether mutation of these residues
may impair the ability of the SID to recruit a functional corepressor
complex, we constructed a minimal SID containing the mutations Q10A,
E14A, and D17A in the context of a GALDBD fusion (Fig. 6A).
This mutant SID (GALSID Q10A, E14A, D17A) repressed transcription to
the same extent as the wild type minimal SID (Fig. 6B),
suggesting that the surface comprised of residues 10, 14, and 17 is
unlikely to make functionally important contacts with other components
of the mSin3A·HDAC complex.

View larger version (17K):
[in a new window]
Fig. 6.
SID 8-20 functions as a portable repression
domain. The reporter plasmid and expression vectors used in this
experiment are shown (A). Transcriptional activity of the
GAL4 DNA binding domain-responsive reporter in the presence of the
expression vectors indicated at the bottom of the figure.
LUC, luciferase; RLU, relative light units
(B).
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-helical structure in solution, and determined
that the hydrophobic face of this helix makes key contacts with mSin3A.
We had previously shown that the amino-terminal 35 residues of Mad1
functions as a portable repression domain and is required to target
functional mSin3A·HDAC complexes (45). Here we show that residues
8-20 of Mad1 constitute a minimal functional portable repression
domain. Further, our experiments showed that residues 10, 14, and 17 are not required for interaction with PAH2 and that the surface created
by these residues does not make important contacts with other
components of the mSin3A·HDAC complex.
-helical
structure and fails to interact with PAH2, suggesting a requirement for
this structure in binding to PAH2. The second class of mutations (A15E
and L19D) retains helical structure in TFE but fails to interact with
PAH2. These mutations are in the hydrophobic face of the SID
amphipathic
-helix demonstrating that the hydrophobic face of the
SID makes key contacts required for high-affinity interaction with
PAH2. We propose that the
-helix correctly positions the hydrophobic
residues of the SID and optimizes the hydrophobic interactions required
for the SID to bind PAH2.
-helix formation even at high concentrations of TFE.
The same proline substituted SID in the context of full-length Mad1
disables both the transcriptional repressor and the biological
functions of Mad1. Furthermore, the SID has been fused to the DNA
binding domain of GAL4, LEXA, and c-Myc and in these contexts can
impart transcriptional repression functions to each of these proteins
(27, 36, 42, 45, 50). In each of these cases, proline substitution of
positions 12 and 16 of the SID result in the loss of repression
function of the fusion proteins. Therefore, there is a strict
correlation between the inability of the L12P/A16P SID peptide to adopt
a helical conformation in TFE and the inability of the SID to function
as an autonomous transcription repression domain. The simplest
interpretation of these results is that the proline-substituted SID, in
the context of the different fusion proteins or full-length Mad1,
cannot adopt the helical conformation that is required for a functional
interaction between the SID and the mSin3A·HDAC corepressor complex.
-helix
when it contacts hTAFII31 (20). In each of these cases,
mutation of hydrophobic residues around the binding interface inhibits
both interaction and transcriptional activation (20, 51, 52). These
findings have led to the conclusion that the charged residues in these
activation domains are generally unimportant for stable interaction and
that interaction is primarily driven by Van der Waals contacts. Our
mutagenesis studies on the SID suggest that similar rules will govern
the interaction between transcription repressors and their
co-repressors.
-helices,
1,
2, and
3.
1 and
3 pack
approximately parallel to one another and are linked by
2, defining
the hydrophobic groove that receives the hydrophobic face of the CREB
KID
-helix (19). Because the linker between the helix A and helix B
of PAH2 can be modeled as an
-helix (data not shown), it is possible
that helix A and B form a hydrophobic cleft, analogous to that found in
the KIX domain, which would receive the hydrophobic face of the
SID.
-helix between amino acids 1833 and 1845 of N-CoR
interrupts interaction with PAH1 (34). These findings suggest that
protein domains that interact with PAH1 and PAH2 may be similar
structurally and distinct from those that interact with PAH3. Current
evidence shows that the interaction between Sin3-binding proteins and
PAH domains is highly specific. For example, no interaction is detected
between Mad1 and PAH1, PAH3 or PAH4 domains of mSin3A using GST
pull-down experiments or directed two-hybrid experiments
(27).2 Therefore, while the
PAH domains may be structurally related, each must have different
requirements for specific protein-protein interaction.
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
Supported by Cancer Center Training Grant 3P30CA42014.
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Kadonaga, J. T.
(1998)
Cell
92,
307-313[CrossRef][Medline]
[Order article via Infotrieve]
2.
Cairns, B. R.
(1998)
Trends Biochem. Sci
23,
20-25[CrossRef][Medline]
[Order article via Infotrieve]
3.
Wu, C.
(1997)
J. Biol. Chem.
272,
28171-28174 4.
Rundlett, S. E.,
Carmen, A. A.,
Kobayashi, R.,
Bavykin, S.,
Turner, B. M.,
and Grunstein, M.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
14503-14508 5.
Zhang, Y.,
LeRoy, G.,
Seelig, H. P.,
Lane, W. S.,
and Reinberg, D.
(1998)
Cell
95,
279-289[CrossRef][Medline]
[Order article via Infotrieve]
6.
Um, M.,
Li, C.,
and Manley, J. L.
(1995)
Mol. Cell. Biol.
15,
5007-5016[Abstract]
7.
Yeung, K. C.,
Inostroza, J. A.,
Mermelstein, F. H.,
Kannabiran, C.,
and Reinberg, D.
(1994)
Genes Dev.
8424,
2097-2109
8.
Auble, D. T.,
Hansen, K. E.,
Mueller, C. G.,
Lane, W. S.,
Thorner, J.,
and Hahn, S.
(1994)
Genes Dev.
8,
1920-1934 9.
Hassig, C. A.,
Fleischer, T. C.,
Billin, A. N.,
Schreiber, S. L.,
and Ayer, D. E.
(1997)
Cell
89,
341-347[CrossRef][Medline]
[Order article via Infotrieve]
10.
Laherty, C. D.,
Yang, W. M.,
Sun, J. M.,
Davie, J. R.,
Seto, E.,
and Eisenman, R. N.
(1997)
Cell
89,
349-356[CrossRef][Medline]
[Order article via Infotrieve]
11.
Brehm, A.,
Miska, E. A.,
McCance, D. J.,
Reid, J. L.,
Bannister, A. J.,
and Kouzarides, T.
(1998)
Nature
391,
597-601[CrossRef][Medline]
[Order article via Infotrieve]
12.
Magnaghi-Jaulin, L.,
Groisman, R.,
Naguibneva, I.,
Robin, P.,
Lorain, S.,
Le Villain, J. P.,
Troalen, F.,
Trouche, D.,
and Harel-Bellan, A.
(1998)
Nature
391,
601-605[CrossRef][Medline]
[Order article via Infotrieve]
13.
Luo, R. X.,
Postigo, A. A.,
and Dean, D. C.
(1998)
Cell
92,
463-473[CrossRef][Medline]
[Order article via Infotrieve]
14.
Jones, P. L.,
Veenstra, G. J.,
Wade, P. A.,
Vermaak, D.,
Kass, S. U.,
Landsberger, N.,
Strouboulis, J.,
and Wolffe, A. P.
(1998)
Nat. Genet.
19,
187-191[CrossRef][Medline]
[Order article via Infotrieve]
15.
Nan, X.,
Ng, H. H.,
Johnson, C. A.,
Laherty, C. D.,
Turner, B. M.,
Eisenman, R. N.,
and Bird, A.
(1998)
Nature
393,
386-389[CrossRef][Medline]
[Order article via Infotrieve]
16.
Paroush, Z.,
Finley, R. L., Jr.,
Kidd, T.,
Wainwright, S. M.,
Ingham, P. W.,
Brent, R.,
and Ish-Horowicz, D.
(1994)
Cell
79,
805-815[CrossRef][Medline]
[Order article via Infotrieve]
17.
Kadosh, D.,
and Struhl, K.
(1997)
Cell
89,
365-371[CrossRef][Medline]
[Order article via Infotrieve]
18.
Kussie, P. H.,
Gorina, S.,
Marechal, V.,
Elenbaas, B.,
Moreau, J.,
Levine, A. J.,
and Pavletich, N. P.
(1996)
Science
274,
948-953 19.
Radhakrishnan, I.,
Perez-Alvarado, G. C.,
Parker, D.,
Dyson, H. J.,
Montminy, M. R.,
and Wright, P. E.
(1997)
Cell
91,
741-752[CrossRef][Medline]
[Order article via Infotrieve]
20.
Uesugi, M.,
Nyanguile, O.,
Lu, H.,
Levine, A. J.,
and Verdine, G. L.
(1997)
Science
277,
1310-1313 21.
Grunstein, M.
(1997)
Nature
389,
349-352[CrossRef][Medline]
[Order article via Infotrieve]
22.
Wolffe, A. P.,
and Pruss, D.
(1996)
Cell
84,
817-819[CrossRef][Medline]
[Order article via Infotrieve]
23.
Hassig, C. A.,
and Schreiber, S. L.
(1997)
Curr. Opin. Chem. Biol.
1,
300-308[CrossRef][Medline]
[Order article via Infotrieve]
24.
Grant, P. A.,
Sterner, D. E.,
Duggan, L. J.,
Workman, J. L.,
and Berger, S. L.
(1998)
Trends Cell Biol.
8,
193-197[CrossRef][Medline]
[Order article via Infotrieve]
25.
Struhl, K.
(1998)
Genes Dev.
12,
599-606 26.
Davie, J. R.
(1998)
Curr. Opin. Genet. Dev.
8,
173-178[CrossRef][Medline]
[Order article via Infotrieve]
27.
Ayer, D. E.,
Lawrence, Q. A.,
and Eisenman, R. N.
(1995)
Cell
80,
767-776[CrossRef][Medline]
[Order article via Infotrieve]
28.
Schreiber-Agus, N.,
Chin, L.,
Chen, K.,
Torres, R.,
Rao, G.,
Guida, P.,
Skoultchi, A. I.,
and DePinho, R. A.
(1995)
Cell
80,
777-786[CrossRef][Medline]
[Order article via Infotrieve]
29.
Zhang, Y.,
Iratni, R.,
Erdjument-Bromage, H.,
Tempst, P.,
and Reinberg, D.
(1997)
Cell
89,
357-364[CrossRef][Medline]
[Order article via Infotrieve]
30.
Laherty, C. D.,
Billin, A. N.,
Lavinsky, R. M.,
Yochum, G. S.,
Bush, A. C.,
Sun, J. M.,
Mullen, T. M.,
Davie, J. R.,
Rose, D. W.,
Glass, C. K.,
Rosenfeld, M. G.,
Ayer, D. E.,
and Eisenman, R. N.
(1998)
Mol. Cell
2,
33-42[CrossRef][Medline]
[Order article via Infotrieve]
31.
Heinzel, T.,
Lavinsky, R. M.,
Mullen, T. M.,
Soderstrom, M.,
Laherty, C. D.,
Torchia, J.,
Yang, W. M.,
Brard, G.,
Ngo, S. D.,
Davie, J. R.,
Seto, E.,
Eisenman, R. N.,
Rose, D. W.,
Glass, C. K.,
and Rosenfeld, M. G.
(1997)
Nature
387,
43-48[CrossRef][Medline]
[Order article via Infotrieve]
32.
Nagy, L.,
Kao, H. Y.,
Chakravarti, D.,
Lin, R. J.,
Hassig, C. A.,
Ayer, D. E.,
Schreiber, S. L.,
and Evans, R. M.
(1997)
Cell
89,
373-380[CrossRef][Medline]
[Order article via Infotrieve]
33.
Wang, H.,
Clark, I.,
Nicholson, P. R.,
Herskowitz, I.,
and Stillman, D. J.
(1990)
Mol. Cell. Biol.
10,
5927-5936 34.
Alland, L.,
Muhle, R.,
Hou, H., Jr.,
Potes, J.,
Chin, L.,
Schreiber-Agus, N.,
and DePinho, R. A.
(1997)
Nature
387,
49-55[CrossRef][Medline]
[Order article via Infotrieve]
35.
Ayer, D. E.,
Kretzner, L.,
and Eisenman, R. N.
(1993)
Cell
72,
211-222[CrossRef][Medline]
[Order article via Infotrieve]
36.
Koskinen, P. J.,
Ayer, D. E.,
and Eisenman, R. N.
(1995)
Cell Growth Differ.
6,
623-629[Abstract]
37.
Lahoz, E. G.,
Xu, L.,
Schreiber-Agus, N.,
and DePinho, R. A.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
5503-5507 38.
Hurlin, P. J.,
Queva, C.,
Koskinen, P. J.,
Steingrimsson, E.,
Ayer, D. E.,
Copeland, N. G.,
Jenkins, N. A.,
and Eisenman, R. N.
(1995)
EMBO J.
14,
5646-5659[Medline]
[Order article via Infotrieve]
39.
Vastrik, I.,
Kaipainen, A.,
Penttila, T. L.,
Lymboussakis, A.,
Alitalo, R.,
Parvinen, M.,
and Alitalo, K.
(1995)
J. Cell Biol.
128,
1197-1208 40.
Zervos, A. S.,
Gyuris, J.,
and Brent, R.
(1993)
Cell
72,
223-232[CrossRef][Medline]
[Order article via Infotrieve]
41.
Hurlin, P. J.,
Queva, C.,
and Eisenman, R. N.
(1997)
Genes Dev
11,
44-58 42.
Roussel, M. F.,
Ashmun, R. A.,
Sherr, C. J.,
Eisenman, R. N.,
and Ayer, D. E.
(1996)
Mol. Cell. Biol.
16,
2796-2801[Abstract]
43.
Hollenberg, S. M.,
Sternglanz, R.,
Cheng, P. F.,
and Weintraub, H.
(1995)
Mol. Cell. Biol.
15,
3813-3822[Abstract]
44.
Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K.
(eds)
(1995)
Current Protocols in Molecular Biology
, John Wiley & Sons, Inc., New York
45.
Ayer, D. E.,
Laherty, C. D.,
Lawrence, Q. A.,
Armstrong, A.,
and Eisenman, R. N.
(1996)
Mol. Cell. Biol.
16,
5772-5781[Abstract]
46.
Wu, C. S.,
Ikeda, K.,
and Yang, J. T.
(1981)
Biochemistry
20,
566-570[CrossRef][Medline]
[Order article via Infotrieve]
47.
Sonnichsen, F. D.,
Van Eyk, J. E.,
Hodges, R. S.,
and Sykes, B. D.
(1992)
Biochemistry
31,
8790-8798[CrossRef][Medline]
[Order article via Infotrieve]
48.
Jasanoff, A.,
and Fersht, A. R.
(1994)
Biochemistry
33,
2129-2135[CrossRef][Medline]
[Order article via Infotrieve]
49.
Kentsis, A.,
and Sosnick, T. R.
(1998)
Biochemistry
37,
14613-14622[CrossRef][Medline]
[Order article via Infotrieve]
50.
Kasten, M. M.,
Ayer, D. E.,
and Stillman, D. J.
(1996)
Mol. Cell. Biol.
16,
4215-4221[Abstract]
51.
Parker, D.,
Jhala, U. S.,
Radhakrishnan, I.,
Yaffe, M. B.,
Reyes, C.,
Shulman, A. I.,
Cantley, L. C.,
Wright, P. E.,
and Montminy, M.
(1998)
Mol. Cell
2,
353-359[CrossRef][Medline]
[Order article via Infotrieve]
52.
Lin, J.,
Chen, J.,
Elenbaas, B.,
and Levine, A. J.
(1994)
Genes Dev.
8,
1235-1246 53.
Hua, Q. X.,
Jia, W. H.,
Bullock, B. P.,
Habener, J. F.,
and Weiss, M. A.
(1998)
Biochemistry
37,
5858-5866[CrossRef][Medline]
[Order article via Infotrieve]
Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
X. Le Guezennec, M. Vermeulen, and H. G. Stunnenberg Molecular characterization of Sin3 PAH-domain interactor specificity and identification of PAH partners Nucleic Acids Res., September 1, 2006; 34(14): 3929 - 3937. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Sans, D. J. Satterwhite, C. A. Stoltzman, K. T. Breen, and D. E. Ayer MondoA-Mlx Heterodimers Are Candidate Sensors of Cellular Energy Status: Mitochondrial Localization and Direct Regulation of Glycolysis. Mol. Cell. Biol., July 1, 2006; 26(13): 4863 - 4871. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Chen and J. J. Bieker Stage-Specific Repression by the EKLF Transcriptional Activator Mol. Cell. Biol., December 1, 2004; 24(23): 10416 - 10424. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tachikawa, O. Schroder, G. Frey, S. P. Briggs, and T. Sera Regulation of the e |